The Clinical Conversation Around TRD Is Shifting — And Ketamine Is Central to It
A new analysis published in Psychiatric Times (April 2026) examines how clinicians can better optimize the use of what researchers now call "more efficacious" treatments for treatment-resistant depression (TRD) — a category that explicitly includes ketamine-based therapies. The piece arrives at a moment when roughly 30% of people diagnosed with major depressive disorder do not respond adequately to two or more standard antidepressants, meeting the clinical threshold for TRD.
The Psychiatric Times commentary focuses on the practical challenge clinicians face: knowing that highly effective options exist, but navigating barriers to actually getting patients onto them in a timely, structured way. Among the treatments spotlighted are IV ketamine infusions and intranasal esketamine (Spravato) — but the broader conversation has clear implications for oral ketamine formats, including tablets and troches, which are increasingly being used in outpatient, at-home, and telehealth-adjacent settings.
Why This Matters for Oral Ketamine Users Specifically
When clinicians talk about "optimizing" TRD treatment, they are often wrestling with two competing pressures: efficacy and access. IV infusions deliver ketamine with the highest bioavailability — close to 100% — but require clinic visits, IV placement, monitoring, and significant cost. Intranasal esketamine (Spravato) sits in a middle tier: FDA-approved, but administered only in certified healthcare settings under observation, with bioavailability around 45%.
Oral ketamine tablets occupy a different position in this spectrum. Bioavailability for oral formulations typically ranges from 17–29%, meaningfully lower than IV or intranasal routes, because the drug undergoes first-pass metabolism in the liver before reaching systemic circulation. This is not a flaw — it is a pharmacokinetic reality that shapes how oral dosing protocols are designed. Clinicians prescribing oral tablets generally compensate with adjusted dosing schedules, often targeting sub-anesthetic plasma levels that are sufficient for antidepressant effect without the dissociative peaks associated with infusion therapy.
What the Psychiatric Times piece implicitly validates is that TRD patients deserve access to the treatment tier that matches their clinical profile — and for many patients, oral tablets represent the most realistic and sustainable entry point into ketamine-assisted care. Lower per-dose cost, no clinic dependency, and compatibility with telehealth prescribing make tablets particularly relevant for patients in underserved geographies or those who cannot take repeated time away from work or caregiving responsibilities.
Dosing and Absorption: What Oral Tablet Users Should Understand
The optimization framing in the Psychiatric Times article has direct practical relevance for how oral ketamine should be taken. Because tablet absorption varies based on stomach contents, individual metabolic rate, and gut transit time, consistency matters enormously. Taking your tablet at roughly the same time each day, under similar conditions (typically fasted or with only a light meal), helps reduce inter-dose variability — a key factor in building a reliable therapeutic response over a course of treatment.
Some prescribers are also exploring sublingual or buccal absorption of crushed or dissolved tablet formulations, which bypasses first-pass metabolism more effectively and can increase bioavailability closer to the troche range (roughly 30–40%). If your prescriber has discussed this option, it is worth understanding that absorption profile changes meaningfully depending on how long the dissolved tablet is held in the mouth before swallowing.
Unlike infusions, which produce rapid and pronounced psychedelic or dissociative effects that require on-site monitoring, oral tablets at therapeutic antidepressant doses typically produce mild to moderate perceptual changes — often described as a gentle mental softening or slight unreality. This lower intensity is part of why the at-home oral model is considered appropriate for carefully screened patients, though it also means the experiential feedback loop is subtler and the therapeutic arc is slower.
The Access Gap Is Still Real — And Guideline Pressure Helps
One of the most important functions of a Psychiatric Times-level analysis is that it reinforces clinical legitimacy. When a respected psychiatric publication calls for broader and faster uptake of efficacious TRD treatments, it creates pressure — on insurers, on healthcare systems, and on primary care providers who may still be defaulting to a third or fourth antidepressant trial rather than referring to a ketamine-specialized provider.
For patients currently navigating TRD, this kind of clinical consensus-building matters. It strengthens the case for insurance coverage of ketamine therapies (still limited and inconsistent in 2026), supports expanded prescribing via telehealth platforms, and reduces the stigma that can still attach to ketamine as a treatment option when patients raise it with skeptical providers.
If you have tried two or more antidepressants without adequate relief, you clinically meet the TRD threshold. That means the treatments being discussed in the Psychiatric Times piece — including oral ketamine — are no longer fringe options but are increasingly supported by clinical evidence and expert guidance as appropriate next steps.
Key Takeaway for Tablet Users
Oral ketamine tablets have lower bioavailability than IV or intranasal routes, but they remain a clinically valid and accessible option for TRD. Consistency in timing and conditions of administration is critical to treatment response. If you have failed two or more antidepressants, ask your provider whether ketamine — in any format — belongs in your treatment plan. Growing clinical consensus supports earlier, not later, escalation to more efficacious therapies like ketamine.
The Bottom Line
The Psychiatric Times analysis does not break new pharmacological ground, but it does something equally valuable: it pushes the clinical community to stop treating highly effective TRD interventions as last resorts. For oral ketamine users, this is meaningful context. The therapy you are using — or considering — is not experimental novelty. It is part of an increasingly mainstream clinical conversation about getting TRD patients to remission faster, more reliably, and through the most accessible route appropriate to their situation. Read the original analysis at Psychiatric Times.
Share